Patents by Inventor Khursheed Anwer
Khursheed Anwer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180303957Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.Type: ApplicationFiled: November 27, 2017Publication date: October 25, 2018Applicant: CLSN Laboratories, Inc.Inventors: Majed MATAR, Jason FEWELL, Danny H. LEWIS, Khursheed ANWER
-
Patent number: 9827331Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.Type: GrantFiled: September 25, 2015Date of Patent: November 28, 2017Assignee: CLSN Laboratories, Inc.Inventors: Majed Matar, Jason Fewell, Danny H. Lewis, Khursheed Anwer
-
Publication number: 20160331686Abstract: The present invention provides compositions of yeast extracellular vesicles comprising biologically active molecules, methods for making the same, and methods for the use of the yeast extracellular vesicles to deliver biologically active molecules to target cells. In addition, the invention provides cells and compositions comprising the biologically active molecules and vesicles, which can be used as transfection reagents. The invention further provides methods for producing said compositions of biologically active molecules with vesicles as well as the cells that produce those compositions. Compositions and methods for delivering biologically active molecules, such as a small molecule, a DNA expression plasmid, an RNA molecule, a peptide, or a protein, to cells and/or tissues are provided.Type: ApplicationFiled: May 11, 2016Publication date: November 17, 2016Applicant: CLSN Laboratories, Inc.Inventors: Kevin J. POLACH, Daniel W. Neef, Jason G. Fewell, Khursheed Anwer
-
Patent number: 9468687Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.Type: GrantFiled: January 6, 2014Date of Patent: October 18, 2016Assignee: CLSN LABORATORIES, INC.Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
-
Publication number: 20160243256Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.Type: ApplicationFiled: September 25, 2015Publication date: August 25, 2016Applicant: CLSN Laboratories, Inc.Inventors: Majed MATAR, Jason Fewell, Danny H. Lewis, Khursheed Anwer
-
Patent number: 9254334Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: GrantFiled: December 18, 2014Date of Patent: February 9, 2016Assignee: CLSN Laboratories, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 9144546Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.Type: GrantFiled: September 6, 2012Date of Patent: September 29, 2015Assignee: CLSN Laboratories, Inc.Inventors: Majed Matar, Jason Fewell, Danny H. Lewis, Khursheed Anwer
-
Publication number: 20150099000Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: December 18, 2014Publication date: April 9, 2015Applicant: CLSN Laboratories, Inc.Inventors: Gregory SLOBODKIN, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8932638Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: GrantFiled: March 8, 2013Date of Patent: January 13, 2015Assignee: CLSN Laboratories, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8900621Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: GrantFiled: March 8, 2013Date of Patent: December 2, 2014Assignee: CLSN Laboratories, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Publication number: 20140186375Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.Type: ApplicationFiled: January 6, 2014Publication date: July 3, 2014Applicant: EGEN, Inc.Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
-
Publication number: 20140050775Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: March 8, 2013Publication date: February 20, 2014Applicant: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8623837Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.Type: GrantFiled: May 17, 2011Date of Patent: January 7, 2014Assignee: Egen, Inc.Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
-
Patent number: 8569065Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.Type: GrantFiled: March 15, 2010Date of Patent: October 29, 2013Assignee: EGEN, Inc.Inventors: Kevin Polach, Jason Fewell, Khursheed Anwer
-
Publication number: 20130251809Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Publication number: 20130164845Abstract: Novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.Type: ApplicationFiled: December 24, 2012Publication date: June 27, 2013Inventors: Kevin Polach, Jason Fewell, Khursheed Anwer, Leslie S. Wilkinson
-
Patent number: 8460696Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: GrantFiled: March 19, 2010Date of Patent: June 11, 2013Assignee: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8445017Abstract: A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes.Type: GrantFiled: September 20, 2011Date of Patent: May 21, 2013Assignee: Egen, Inc.Inventors: Gregory Slobodkin, Majed Matar, Jason Fewell, Khursheed Anwer
-
Publication number: 20130065942Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.Type: ApplicationFiled: September 6, 2012Publication date: March 14, 2013Applicant: Egen, Inc.Inventors: Majed Matar, Jason Fewell, Danny H. Lewis, Khursheed Anwer
-
Publication number: 20120009145Abstract: A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes.Type: ApplicationFiled: September 20, 2011Publication date: January 12, 2012Inventors: Gregory Slobodkin, Majed Matar, Jason Fewell, Khursheed Anwer